Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CARM Carisma Therapeutics	$0.29 +2.3%	$0.40	$0.14 ▼ $1.27	$12.20M	1.79	393,262 shs	263,072 shs
EVGN Evogene	$1.35 -0.7%	$1.36	$0.95 ▼ $4.18	$7.24M	1.59	85,390 shs	39,435 shs
SLGL Sol-Gel Technologies	$15.44 +1.2%	$9.67	$4.01 ▼ $16.89	$43.01M	1.21	19,615 shs	11,954 shs
VTVT vTv Therapeutics	$15.85 +3.6%	$15.55	$12.62 ▼ $26.99	$49.32M	0.57	1,339 shs	859 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CARM Carisma Therapeutics	+2.35%	+8.15%	-27.72%	+75.48%	-71.09%
EVGN Evogene	-0.74%	+11.57%	+8.00%	+3.05%	-67.47%
SLGL Sol-Gel Technologies	+1.25%	-3.44%	+88.87%	+106.69%	+286.00%
VTVT vTv Therapeutics	+3.59%	+12.37%	-6.71%	-24.63%	+19.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CARM Carisma Therapeutics	3.1788 of 5 stars	3.4	5.0	3.3	0.8	0.6
EVGN Evogene	2.9429 of 5 stars	3.8	3.0	4.1	0.0	0.6
SLGL Sol-Gel Technologies	2.9176 of 5 stars	3.5	3.0	4.3	1.7	0.0
VTVT vTv Therapeutics	1.691 of 5 stars	3.5	3.0	1.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CARM Carisma Therapeutics	2.71	Moderate Buy	$1.93	559.25% Upside
EVGN Evogene	3.50	Strong Buy	$3.50	159.26% Upside
SLGL Sol-Gel Technologies	3.00	Buy	$40.00	159.07% Upside
VTVT vTv Therapeutics	3.00	Buy	$35.50	123.97% Upside

Current Analyst Ratings Breakdown

Latest CARM, EVGN, VTVT, and SLGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	VTVT vTv Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00
8/11/2025	EVGN Evogene	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/8/2025	CARM Carisma Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$1.00
7/15/2025	CARM Carisma Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/22/2025	EVGN Evogene	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$5.00 ➝ $3.50

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CARM Carisma Therapeutics	$19.63M	0.62	N/A	N/A	($1.10) per share	-0.27
EVGN Evogene	$8.51M	0.85	N/A	N/A	$2.77 per share	0.49
SLGL Sol-Gel Technologies	$11.54M	3.73	N/A	N/A	$10.36 per share	1.49
VTVT vTv Therapeutics	$1.02M	49.57	N/A	N/A	$0.75 per share	21.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CARM Carisma Therapeutics	-$60.48M	-$1.56	N/A	N/A	N/A	-254.28%	N/A	-211.28%	N/A
EVGN Evogene	-$16.49M	-$2.69	N/A	∞	N/A	-224.82%	-102.40%	-39.19%	8/19/2025 (Estimated)
SLGL Sol-Gel Technologies	-$10.58M	-$4.70	N/A	N/A	N/A	-107.78%	-43.98%	-35.28%	N/A
VTVT vTv Therapeutics	-$18.46M	-$3.12	N/A	∞	N/A	N/A	-179.75%	-55.91%	N/A

Latest CARM, EVGN, VTVT, and SLGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2025	Q2 2025	EVGN Evogene	-$0.63	N/A	N/A	N/A	$0.93 million	N/A
8/15/2025	Q4 2024	SLGL Sol-Gel Technologies	-$0.67	$4.17	+$4.84	$4.17	$2.86 million	$17.26 million
8/12/2025	Q2 2025	VTVT vTv Therapeutics	-$0.85	-$0.92	-$0.07	-$0.92	N/A	N/A
5/23/2025	Q1 2025	SLGL Sol-Gel Technologies	N/A	-$3.20	N/A	-$3.20	N/A	$1.03 million
5/21/2025	Q1 2025	EVGN Evogene	-$0.50	-$0.38	+$0.12	-$0.38	$4.42 million	$2.44 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CARM Carisma Therapeutics	N/A	N/A	N/A	N/A	N/A
EVGN Evogene	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A
VTVT vTv Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CARM Carisma Therapeutics	N/A	0.48	0.48
EVGN Evogene	N/A	1.06	0.92
SLGL Sol-Gel Technologies	N/A	5.12	5.12
VTVT vTv Therapeutics	N/A	4.98	7.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CARM Carisma Therapeutics	44.27%
EVGN Evogene	10.40%
SLGL Sol-Gel Technologies	26.18%
VTVT vTv Therapeutics	17.51%

Insider Ownership

Company	Insider Ownership
CARM Carisma Therapeutics	6.90%
EVGN Evogene	7.40%
SLGL Sol-Gel Technologies	66.51%
VTVT vTv Therapeutics	4.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CARM Carisma Therapeutics	20	41.79 million	38.91 million	No Data
EVGN Evogene	140	5.37 million	4.97 million	Optionable
SLGL Sol-Gel Technologies	50	2.79 million	933,000	Optionable
VTVT vTv Therapeutics	9	3.19 million	3.06 million	Not Optionable

CARM, EVGN, VTVT, and SLGL Headlines

Recent News About These Companies

vTv Therapeutics (NASDAQ:VTVT) Receives Buy Rating from HC Wainwright

August 15 at 2:51 AM | americanbankingnews.com

vTv Therapeutics Inc.: vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13 at 7:47 AM | finanznachrichten.de

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12, 2025 | globenewswire.com

vTv Therapeutics Inc.: vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

August 11, 2025 | finanznachrichten.de

vTv Therapeutics Receives Notice of Allowance for Cadisegliatin Patent, Strengthening Protection for Type 1 Diabetes Treatment

August 11, 2025 | quiverquant.comQ

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

August 11, 2025 | globenewswire.com

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

August 7, 2025 | globenewswire.com

vTv Therapeutics (VTVT) Expected to Announce Quarterly Earnings on Thursday

August 7, 2025 | americanbankingnews.com

vTv Therapeutics (NASDAQ:VTVT) Share Price Passes Below 50 Day Moving Average - Here's Why

July 26, 2025 | marketbeat.com

vTv Therapeutics (NASDAQ:VTVT) Share Price Crosses Below 50-Day Moving Average - Time to Sell?

July 17, 2025 | marketbeat.com

vTv Therapeutics Inc (VTVT) Share Chat - Investing.com UK

June 29, 2025 | uk.investing.com

VTVT - vTv Therapeutics Inc Class A Chart - Morningstar

June 27, 2025 | morningstar.comM

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

June 11, 2025 | globenewswire.com

vTv resumes Phase III oral T1D drug study

May 21, 2025 | thepharmaletter.comT

vTv Therapeutics Appoints Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer

May 19, 2025 | quiverquant.comQ

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 19, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (VTVT) and Precision BioSciences (DTIL)

May 17, 2025 | theglobeandmail.com

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025 | globenewswire.com

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

May 15, 2025 | globenewswire.com

vTv Therapeutics Appoints Barry Brown as Interim CFO

April 11, 2025 | tipranks.com

vTv Therapeutics initiated with a Buy at H.C. Wainwright

April 9, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARM, EVGN, VTVT, and SLGL Company Descriptions

Carisma Therapeutics NASDAQ:CARM

$0.29 +0.01 (+2.35%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$0.29 0.00 (-0.68%)

As of 08/15/2025 07:30 PM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Evogene NASDAQ:EVGN

$1.35 -0.01 (-0.74%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.39 +0.04 (+2.96%)

As of 08/15/2025 05:50 PM Eastern

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Sol-Gel Technologies NASDAQ:SLGL

$15.44 +0.19 (+1.25%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$15.30 -0.15 (-0.94%)

As of 08/15/2025 06:51 PM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

vTv Therapeutics NASDAQ:VTVT

$15.85 +0.55 (+3.59%)

Closing price 08/15/2025 03:55 PM Eastern

Extended Trading

$15.85 0.00 (0.00%)

As of 08/15/2025 04:10 PM Eastern

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time